AMGN
AMGEN
Stock NASDAQ – Stock Market Prices, News & Analysis
Amgen is a global leader in biotechnology, developing innovative treatments for serious diseases in various areas such as oncology, cardiology, and neurology.
AMGEN
AMGN
Amgen is a global leader in biotechnology, developing innovative treatments for serious diseases in various areas such as oncology, cardiology, and neurology.
Price history of AMGEN
Price history of AMGEN
Performance & Momentum
Amgen Set to Slash Amjevita via TrumpRx
Amgen is expected to join the TrumpRx program alongside GSK to offer steep discounts on prescription drugs. According to reports, Amgen would notably offer an 80% cut on Amjevita, its treatment for rheumatoid arthritis, psoriasis and ulcerative colitis. The move could improve patient access and strengthen ties with regulators, but it may also weigh on the group’s margins and revenue in the near term. For AMGN shares, the market reaction could be mixed to negative if investors focus mainly on the impact on profitability.
Strategic Analysis
AMGEN • 2026
Amgen is positioned as a key player in U.S. biotechnology, specializing in the development of innovative treatments for serious diseases in oncology, cardiology, and neurology. Its model is based on strong innovation capabilities combined with broad therapeutic diversification, ensuring a stable presence in high-value segments.
- Recognized leadership in several major therapeutic areas such as oncology and cardiology
- Sustained innovation capacity with a robust pipeline supporting medium- and long-term growth
- Diversified portfolio that reduces dependence on a single market segment
- Intense competition in biotechnology, particularly from emerging innovative players
- Risks related to regulation and the high cost of pharmaceutical development
Amgen’s momentum is solid and improving, supported by a positive trend across multiple time horizons. This dynamic reflects market confidence in its operational outlook and medium-term growth potential, with no recent specific event altering this trajectory.
Similar stocks to AMGEN
Recent News
AMGEN
Amgen Raises $4B in Long-Term Bonds to Fund Growth
1 month agoOn February 17, 2026, Amgen raised approximately $3.96 billion through a multi-tranche bond issuance with maturities extending to 2056. This move reflects the company’s strategy to optimize its capital structure to support its long-term investment plans. Additionally, Amgen shares benefit from a bullish sentiment, boosted by an attractive valuation with a forward P/E ratio around 13.74, appealing to value-seeking investors in the biotech sector. This positive momentum could support AMGN stock on the NASDAQ in the coming months.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
